Joseph Stringer
Stock Analyst at Needham
(4.89)
# 303
Out of 5,134 analysts
627
Total ratings
48%
Success rate
23.7%
Average return
Main Sectors:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Reiterated: Buy | $170 → $200 | $168.08 | +18.99% | 32 | Oct 30, 2026 | |
| CAMP Camp4 Therapeutics | Initiated Coverage: Buy | $8 | $3.80 | +110.53% | 1 | Oct 15, 2026 | |
| PCVX Vaxcyte | Rated: Buy | $110 → $122 | $63.37 | +92.52% | 44 | Oct 5, 2026 | |
| STTK Shattuck Labs | Rated: Buy | $17 → $19 | $4.65 | +308.60% | 7 | Oct 2, 2026 | |
| VIR Vir Biotechnology | Reiterated: Buy | $18 | $9.96 | +80.72% | 48 | Sep 28, 2026 | |
| IONS Ionis Pharmaceuticals | Reiterated: Buy | $86 | $29.06 | +195.94% | 47 | Sep 23, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $357 | $165.04 | +116.31% | 49 | Sep 17, 2026 | |
| BIOA BioAge Labs | Reiterated: Buy | $35 | $5.55 | +530.63% | 8 | Sep 14, 2026 | |
| IFRX InflaRx | Initiated Coverage: Buy | $8 | $1.17 | +583.76% | 1 | Sep 14, 2026 | |
| MRNA Moderna | Reiterated: Hold | n/a | $223.37 | - | 44 | Aug 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $3.92 | +537.76% | 39 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.697 | - | 34 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $130 | $115.02 | +13.02% | 48 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $26.68 | +49.93% | 46 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $538.60 | - | 33 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 → $22 | $6.06 | +263.04% | 75 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.79 | n/a | 28 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.18 | n/a | 33 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $26 | $18.75 | n/a | 5 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $167.40 | n/a | 3 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $170 | $42.24 | n/a | 2 | Apr 28, 2021 |
Gilead Sciences
Oct 30, 2026
Reiterated: Buy
Price Target: $170 → $200
Current: $168.08
Upside: +18.99%
Camp4 Therapeutics
Oct 15, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $3.80
Upside: +110.53%
Vaxcyte
Oct 5, 2026
Rated: Buy
Price Target: $110 → $122
Current: $63.37
Upside: +92.52%
Shattuck Labs
Oct 2, 2026
Rated: Buy
Price Target: $17 → $19
Current: $4.65
Upside: +308.60%
Vir Biotechnology
Sep 28, 2026
Reiterated: Buy
Price Target: $18
Current: $9.96
Upside: +80.72%
Ionis Pharmaceuticals
Sep 23, 2026
Reiterated: Buy
Price Target: $86
Current: $29.06
Upside: +195.94%
Alnylam Pharmaceuticals
Sep 17, 2026
Reiterated: Buy
Price Target: $357
Current: $165.04
Upside: +116.31%
BioAge Labs
Sep 14, 2026
Reiterated: Buy
Price Target: $35
Current: $5.55
Upside: +530.63%
InflaRx
Sep 14, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $1.17
Upside: +583.76%
Moderna
Aug 19, 2026
Reiterated: Hold
Price Target: n/a
Current: $223.37
Upside: -
Aug 12, 2026
Reiterated: Buy
Price Target: $25
Current: $3.92
Upside: +537.76%
Aug 12, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.697
Upside: -
Aug 4, 2026
Reiterated: Buy
Price Target: $130
Current: $115.02
Upside: +13.02%
Aug 4, 2026
Reiterated: Buy
Price Target: $40
Current: $26.68
Upside: +49.93%
Aug 4, 2026
Reiterated: Hold
Price Target: n/a
Current: $538.60
Upside: -
Jul 30, 2026
Reiterated: Buy
Price Target: $28 → $22
Current: $6.06
Upside: +263.04%
Apr 21, 2025
Rated: Hold
Price Target: n/a
Current: $1.79
Upside: n/a
Aug 16, 2024
Rated: Hold
Price Target: n/a
Current: $1.18
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $30 → $26
Current: $18.75
Upside: n/a
Aug 4, 2021
Rated: Hold
Price Target: n/a
Current: $167.40
Upside: n/a
Apr 28, 2021
Rated: Buy
Price Target: $170
Current: $42.24
Upside: n/a